Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma

被引：5
|
作者：
Marr, Kristin [1 ]
Ronsley, Rebecca [1 ]
Nadel, Helen [2 ]
Douglas, Kate [1 ]
Gershony, Sharon [3 ]
Strahlendorf, Caron [1 ,4 ]
Davis, Jeffrey H. [1 ]
Deyell, Rebecca J. [1 ,4 ]
机构：
[1] Univ British Columbia, British Columbia Childrens Hosp, Div Pediat Hematol Oncol & Bone Marrow Transplant, Vancouver, BC, Canada
[2] Stanford Univ, Dept Radiol, Div Nucl Med, Stanford, CA 94305 USA
[3] Univ British Columbia, Dept Radiol, Div Nucl Med, Vancouver, BC, Canada
[4] Univ British Columbia, Child & Family Res Inst, Michael Cuccione Childhood Canc Res Program, Vancouver, BC, Canada
来源：
PEDIATRIC BLOOD & CANCER | 2020年 / 67卷 / 04期
关键词：
autologous stem cell transplantation; Hodgkin lymphoma; IGEV; pediatric; HIGH-DOSE THERAPY; CHILDREN; TRANSPLANTATION; DISEASE; ADOLESCENTS; CHEMOTHERAPY; RECURRENT;
D O I：
10.1002/pbc.28167
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We describe 12 pediatric patients (8-16 years) with primary refractory (N = 6) or first relapse (N = 6) Hodgkin lymphoma (HL) treated with ifosfamide, gemcitabine, and vinorelbine (IGEV). The overall response rate to IGEV was 100%, with seven (58%) complete responses (CR) and five (42%) partial responses. Successful CD34(+) stem cell mobilization was achieved in all patients. Following subsequent autologous stem cell transplantation, 10 patients (83%) achieved CR. At a median follow-up of 71 months, 11 patients had no evidence of disease. Five-year second event-free survival and overall survival were 83% +/- 11.0% and 90.0% +/- 9.5%, respectively. IGEV is an effective salvage regimen for children with relapsed/refractory HL.
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
    Santoro, Armando
    Mazza, Rita
    Pulsoni, Alessandro
    Re, Alessandro
    Bonfichi, Maurizio
    Zilioli, Vittorio Ruggeri
    Salvi, Flavia
    Anastasia, Antonella
    Luminari, Stefano
    Gotti, Manuel
    Peli, Annalisa
    Liberati, Anna Marina
    Di Renzo, Nicola
    Castagna, Luca
    Giordano, Laura
    Carlo-Stella, Carmelo
    BLOOD, 2015, 126 (23)
  • [22] Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease
    Bonfante, V
    Viviani, S
    Santoro, A
    Devizzi, L
    Di Russo, A
    Zanini, M
    Soncini, F
    Parra, HS
    Valagussa, P
    Bonadonna, G
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (02) : 533 - 535
  • [23] Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective salvage regimen for relapsed and refractory Hodgkin and non-Hodgkin's lymphoma: Results of a pilot study
    Corazzelli, G.
    Capobianco, G.
    Marcacci, G.
    Frigeri, F.
    Arcamone, M.
    Becchimanzi, C.
    Pinto, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 235 - 235
  • [24] Gemcitabine in Combination with Oxaliplatin (GEMOX) As a Salvage Regimen in Patients with Relapsed/Refractory Hodgkin's Lymphoma
    Ozdemir, Evren
    Aslan, Alma
    Turker, Alev
    Barista, Ibrahim
    Kars, Ayse
    BLOOD, 2015, 126 (23)
  • [25] Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) is an Effective Regimen for Heavily Pretreated, Relapsed or Refractory Hodgkin Lymphoma Patients: A Retrospective Study
    Russo, Antonio
    Ricci, Francesca
    Magagnoli, Massimo
    Rodari, Marcello
    Morello, Lucia
    Mazza, Rita
    Chiti, Arturo
    Castagna, Luca
    Santoro, Armando
    Carlo-Stella, Carmelo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S234 - S234
  • [26] Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
    Khadega A. Abuelgasim
    Mohsen Alzahrani
    Yousef Alsharhan
    Moataz Khairi
    Mohammed Hommady
    Giamal Gmati
    Hind Salama
    Osama Ali
    Bader Alahmari
    Emad M. Masuadi
    Ahmed Alaskar
    Ayman Alhejazi
    Moussab Damlaj
    Bone Marrow Transplantation, 2019, 54 : 1168 - 1172
  • [27] Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
    Abuelgasim, Khadega A.
    Alzahrani, Mohsen
    Alsharhan, Yousef
    Khairi, Moataz
    Hommady, Mohammed
    Gmati, Giamal
    Salama, Hind
    Ali, Osama
    Alahmari, Bader
    Masuadi, Emad M.
    Alaskar, Ahmed
    Alhejazi, Ayman
    Damlaj, Moussab
    BONE MARROW TRANSPLANTATION, 2019, 54 (07) : 1168 - 1172
  • [28] Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
    Bartlett, N. L.
    Niedzwiecki, D.
    Johnson, J. L.
    Friedberg, J. W.
    Johnson, K. B.
    van Besien, K.
    Zelenetz, A. D.
    Cheson, B. D.
    Canellos, G. P.
    ANNALS OF ONCOLOGY, 2007, 18 (06) : 1071 - 1079
  • [29] Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma: a single-center experience
    Prakash, Gaurav
    Jain, Arihant
    Sahu, Kamalkant
    Bal, Amanjit
    Singh, Charanpreet
    Basher, Rajender
    Singh, Harmandeep
    Mishra, Kundan
    Jandial, Aditya
    Lad, Deepesh
    Khadwal, Alka
    Srinivasan, Radhika
    Das, Ashim
    Varma, Neelam
    Varma, Subhash
    Malhotra, Pankaj
    BLOOD RESEARCH, 2021, 56 (03) : 134 - 140
  • [30] Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-hodgkin lymphoma: A salvage regimen with high response rates before autologous stem cell transplantation
    Oyan, B
    Koc, Y
    Ozdemir, E
    Kars, A
    Turker, A
    Tekuzman, G
    Kansu, E
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (09) : 688 - 697
12345